| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/03/2009 | US7485706 Has a domain that preferentially binds to aggregations comprising at least two monomeric proteins linked to a second domain that recruits the aggregation modifying protein; neurotoxicity; neurodegenerative diseases |
| 02/03/2009 | US7485669 Blockade of sodium channels by phenol derivatives |
| 02/03/2009 | US7485668 Cyclopropanated macrocyclic ketones and lactones |
| 02/03/2009 | US7485667 rheumatoid arthritis, graft rejection, cachexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, CNS disorders, inflammatory bowel disease, HIV infection; TNF- alpha converting enzyme inhibitors;3-[(hydroxyamino)carbonyl]-2-naphthyl 4-(2-butynyloxy)benzenesulfonate |
| 02/03/2009 | US7485666 Vaginal health products |
| 02/03/2009 | US7485665 Medicinal composition |
| 02/03/2009 | US7485664 Inhibitors of TACE |
| 02/03/2009 | US7485663 dissolving in a solvent, precipitating crystal form by cooling the solution to about -20C |
| 02/03/2009 | US7485662 for improving insulin resistance; food and drink additives, and feeds or feed additives for treating diabetes mellitus; cis-4-hydroxy-L-proline, cis-4-hydroxy-D-proline, cis-3-hydroxy-L-proline, cis-3-hydroxy-D-proline, trans-4-hydroxy-L-proline, trans-4-hydroxy-D-proline, trans-3-hydroxy-L-proline ETC. |
| 02/03/2009 | US7485661 Heterobicyclic pyrazole derivatives as kinase inhibitors |
| 02/03/2009 | US7485660 For selectively modulating the activation, repression, agonism and antagonism effects of the glucocorticoid receptor in a patient; for therapy and prophylaxis of obesity, diabetes, depression, neurodegeneration or an inflammatory disease |
| 02/03/2009 | US7485659 Anticancer compositions, and methods of making and using the same |
| 02/03/2009 | US7485658 N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors |
| 02/03/2009 | US7485657 Anti-cytokine heterocyclic compounds |
| 02/03/2009 | US7485656 Fluconazole, a compound selected from a group consisting of fatty acid, fatty alcohol, higher fatty acid ester and lower alcohol and a base; favorable absorption and delivery through the human skin; low skin stimulation; stability; spreading |
| 02/03/2009 | US7485655 2-Aminothiazole allosteric enhancers of A1 adenosine receptors |
| 02/03/2009 | US7485654 Corneal perception recovery drug containing amide compound |
| 02/03/2009 | US7485653 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease |
| 02/03/2009 | US7485652 Indolyl derivatives as liver-X-receptor (LXR) modulators |
| 02/03/2009 | US7485651 Cholinergic agents such as 4-Butyl-1-(4-phenyl-4-oxo-1-butyl) piperidine, administered as cognition activators and for prophylaxis of vision defects |
| 02/03/2009 | US7485650 High affinity ligands for nociceptin receptor ORL-1 |
| 02/03/2009 | US7485649 Inhibitors of checkpoint kinases |
| 02/03/2009 | US7485648 pyridine or pyrimidine thieno(2,3-e)pyrimidine tricyclic compounds; metabotropic glutamate receptor antagonist; analgesic, anxiolytic agent: pain, migraine, urinary incontinence; neurodegenerative diseases: Alzheimer's disease |
| 02/03/2009 | US7485647 2-aminoquinoline derivatives |
| 02/03/2009 | US7485646 Serotonin 5-HT3 receptor agonist |
| 02/03/2009 | US7485645 prostate cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, androgenic alopecia, precocious puberty, adrenal hyperlasia and polycystic ovarian syndrome, breast cancer, endometriosis, leiomyoma and precocious puberty, estrogen dependent diseases |
| 02/03/2009 | US7485644 hydroxy{(1S)-4-pyrimidin-2-yl-1-[({4-[5-(2,2,2-trifluoroethoxy)pyrimidin-2-yl]piperazin-1-yl}sulfonyl)methyl]butyl}formamide; collagenase 3 inhibitor; tissue remodelling such as embryonic development, bone formation and uterine remodelling during menstruation |
| 02/03/2009 | US7485643 Bicyclic inhibitors of MEK and methods of use thereof |
| 02/03/2009 | US7485642 Administering levosimendan or a salt thereof |
| 02/03/2009 | US7485641 Substituted 3-amino-pyrrolidino-4-lactams |
| 02/03/2009 | US7485640 e.g. 2'-fluoro-5'-(7-methyl-8-oxo-7,8-dihydroimidazo[1,2-a]pyrazin-3-yl)-biphenyl-2-carbonitrile; anticonvulsant |
| 02/03/2009 | US7485639 Well tolerated; intracellularly increasing cAMP; antiasthmatics, antiinflammatories: regulation of eosinophiles activation and degranulation |
| 02/03/2009 | US7485638 Pyrimidine compounds |
| 02/03/2009 | US7485637 Benzoyl-tetrahydropiperidine derivatives |
| 02/03/2009 | US7485636 Therapeutic pyrazolo[3,4-b]pyridines and indazoles |
| 02/03/2009 | US7485635 e.g. Methyl 3-[8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidzao[1,2-a][1,4]benzodiazepine-4-yl]propanoate; GABAA (gamma aminobutiric acid) receptor antagonist; sedative-hypnotic, anxiolytic, muscle relaxant and anticonvulsant; anesthesia |
| 02/03/2009 | US7485634 Methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of |
| 02/03/2009 | US7485633 Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| 02/03/2009 | US7485632 Cephalosporins |
| 02/03/2009 | US7485631 macrolactone antibiotics; Phorboxazole mimetics; carcinogenic agent; cancer cell division inhibitor; pancreatic, breast, non-small lung, colon, and prostate cancers, leukemia |
| 02/03/2009 | US7485630 e.g. 2-{[(3'-Amino-1'-aza-2'-oxobicyclo[6.3.0]-undecyl)-11'-carbonyl]amino}-1,5-pentanedioic acid; tripeptide Gly-Pro-Glu (GPE) mimetic; enzymatic degradation, ischemic injury, hypoxic injury, reperfusion injury, and asphyxia |
| 02/03/2009 | US7485629 Composition and method for treatment of joint damage |
| 02/03/2009 | US7485628 Inhibition of STAT-1 |
| 02/03/2009 | US7485627 Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
| 02/03/2009 | US7485626 Biosynthesis of Dna ; cell proliferation; overlapping enzyme activation ; mixture of proteolytic enzyme and dipeptidyl peptidase inhibitors; autoimmune disease; antiinflammatory agents graft versus host diease |
| 02/03/2009 | US7485625 Inhibitors of hepatitis C virus NS3/NS4a serine protease |
| 02/03/2009 | US7485623 administering 4-hydroxy tamoxifen percutaneously to a patient having dense breast tissue; 4-hydroxy tamoxifen may be formulated in a hydroalcoholic gel or an alcoholic solution |
| 02/03/2009 | US7485456 Drug screening for a molecule capable of binding to NIK (nuclear factor kappa B inducing kinase); DNA sequence encoding a protein capable of binding to a tumor necrosis factor receptor-associated factor (TRAF) molecule, TRAF-binding proteins, isoforms, analogs, fragments and derivatives; gene expression |
| 02/03/2009 | US7485432 Selective modulation of TLR-mediated biological activity |
| 02/03/2009 | US7485422 Using aberrant expression of caudal type homeobox transcription factor 2 (CDX2) as diagnostic indicator of stomach or esophageal cell proliferative disorers |
| 02/03/2009 | US7485327 For use in pharmaceuticals, dietetics and/or cosmetics; anticancer agents; for treatment of vision defects and periodontal disease |
| 02/03/2009 | US7485326 Oral microemulsion composition comprising biphenyldimethyldicarboxylate and silybin |
| 02/03/2009 | US7485320 Liposome for incorporating large amounts of hydrophobic substances |
| 02/03/2009 | US7485319 Doxycycline metal complex in a solid dosage form |
| 02/03/2009 | US7485315 Compositions comprising a compound of low solubility and a lipophilic amino acid derivative, uses thereof and process for dissolving a compound of low solubility |
| 02/03/2009 | US7485314 Induction of antigen specific immunologic tolerance |
| 02/03/2009 | US7485296 Using monoclonal antibodies specific for prostate stem cell antigen (PSCA) for use in diagnosis and treatment of cell proliferfative disorders; immunodiagnostics; immunotherapy |
| 02/03/2009 | US7485292 Administering echovirus which recognizes integrin alpha 2 beta 1 for infectivity of the cells such that at least one of the cells are killed by the virus, wherein the abnormal cell is a cancer cell expressing alpha 2 beta 1; screening viruses |
| 02/03/2009 | US7485285 Delivery of antidepressants through an inhalation route |
| 02/03/2009 | US7485283 imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging. |
| 02/03/2009 | CA2538905C Withanamide glycoside and compositions and methods of use thereof |
| 02/03/2009 | CA2478302C 9-aminoacridine derivatives and process for the preparation thereof |
| 02/03/2009 | CA2478146C Spiro and dispiro 1,2,4-trioxolane antimalarials |
| 02/03/2009 | CA2455208C Method of encapsulating an active substance |
| 02/03/2009 | CA2446615C Nutritional composition for the treatment of connective tissue |
| 02/03/2009 | CA2441613C Novel amlodipine camsylate and method for preparing thereof |
| 02/03/2009 | CA2425164C (4-acylaminopiperidin-1-yl)acetamides as neurokinin antagonists |
| 02/03/2009 | CA2420040C New phenylalanine derivatives |
| 02/03/2009 | CA2412055C Double salts of fumaric acid with a carnitine and an amino acid and food supplements, dietary supplements and drugs containing same |
| 02/03/2009 | CA2410554C Use of (+)-.alpha. -(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis |
| 02/03/2009 | CA2409869C Novel solid body forms of mesoprogestin 11.beta.-[4e-(hydroxyiminomethyl)-phenyl]-17.alpha.-methoxymethyl-17.beta.-methoxy-estra-4,9-dien-3-one |
| 02/03/2009 | CA2395881C Inhalation particles |
| 02/03/2009 | CA2392804C Combined agents for treatment of glaucoma |
| 02/03/2009 | CA2390463C 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
| 02/03/2009 | CA2388244C Agents for promoting fattening of animals and method of promoting fattening |
| 02/03/2009 | CA2382902C Rapidly decomposing chitosan-based pellets |
| 02/03/2009 | CA2377686C Mercaptoacylcysteine derivatives as therapeutic agents for osteoarthritis |
| 02/03/2009 | CA2355745C Soybean-germ oil and method for the production of germ-enriched soybean material |
| 02/03/2009 | CA2355359C Use of riluzole for treating acoustic traumas |
| 02/03/2009 | CA2354042C Bioflavonoids, anthocyanins and phenolic compounds from cherries for inhibiting inflammation |
| 02/03/2009 | CA2352786C Benzofuran derivatives, process for the preparation of the same and uses thereof |
| 02/03/2009 | CA2341397C Immediate release tablet |
| 02/03/2009 | CA2334821C Chemical synthesis of morpholine derivatives |
| 02/03/2009 | CA2323150C New porphyrins and their use |
| 02/03/2009 | CA2322868C Acylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| 02/03/2009 | CA2315050C Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof |
| 02/03/2009 | CA2314716C Modified polysaccharides exhibiting altered biological recognition |
| 02/03/2009 | CA2314607C Use of ppar-.gamma. activators in dermatology |
| 02/03/2009 | CA2301082C Anti-cancer compounds |
| 02/03/2009 | CA2299271C Prodrugs and conjugates of thiol- and selenol- containing compounds and methods of use thereof |
| 02/03/2009 | CA2289717C Novel therapy for constipation |
| 02/03/2009 | CA2282654C Use of cholinesterase inhibitors to treat attention deficit hyperactivity disorder |
| 02/03/2009 | CA2275321C Medical composition and use thereof for the manufacture of a topical barrier formulation, a uv-radiation absorbing formulation, or an antiviral, antifungal, or antiinflammatory formulation |
| 02/03/2009 | CA2274686C Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds |
| 02/03/2009 | CA2259936C Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents |
| 02/01/2009 | CA2638158A1 Extracts rich in proanthocyanidins and relating process of preparation |
| 02/01/2009 | CA2595485A1 Liposomal compositions for parenteral delivery of statins |
| 01/30/2009 | CA2712022A1 Enantiomerically pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4h-pyrido[1,2-a]pyrimidin-9-yl)ethylamino]benzoic acid, its use in medical therapy, and a pharmaceutical composition comprising it - 026 |
| 01/29/2009 | WO2009015372A1 Photo-protective dermatological formulations and methods of using the same |
| 01/29/2009 | WO2009015368A2 Multikinase inhibitors for use in the treatment of cancer |